Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v

SOT201 represents a promising therapeutic candidate that preferentially targets PD-1<sup>+</sup> TILs, delivering balanced cytokine activity for reviving CD8<sup>+</sup> Tex cells in tumors. SOT201 is currently being evaluated in the Phase I clinical study VICTORIA-01 (NCT06163391) in patients with advanced metastatic cancer.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-04-01
DOI
https://doi.org/10.1136/jitc-2024-010736
Citations
5
Primary Topic
Immune Cell Function and Interaction
Type
article
Field-Weighted Citation Impact
3.99

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v

Romana Mikyšková, Radek Špíšek, Kamila Hladíková, Klára Dáňová et al.
5 citations
Journal for ImmunoTherapy of Cancer
Immune Cell Function and Interaction
3.99
article

Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v

Romana Mikyšková, Radek Špíšek, Kamila Hladíková, Klára Dáňová, Hana Matušková, Milada Šírová, Matej Fabišik, David Béchard, Lucie Košinová, Nada Podzimkova, Petr Daněk, Milan Reiniš, Dario Greco, Vladyslav Mazhara, Martin Steegmaier, Irena Adkins, Pavel Marášek, Zuzana Antosova, Ulrich Moebius, Marek Kovář, Katerina Sajnerova, Iva Malatova, Kateřina Běhalová, Lenka Palová Jelínková, Ekaterina Simonova, Klara Hrabankova, Ondrej Martinec
article en
5 citations

Abstract

SOT201 represents a promising therapeutic candidate that preferentially targets PD-1<sup>+</sup> TILs, delivering balanced cytokine activity for reviving CD8<sup>+</sup> Tex cells in tumors. SOT201 is currently being evaluated in the Phase I clinical study VICTORIA-01 (NCT06163391) in patients with advanced metastatic cancer.

Journal for ImmunoTherapy of CancerVol. 13(4)
Czech Academy of Sciences (CZ), Charles University (CZ), Institute of Microbiology (BY), ATLAB Pharma (France) (FR), Sotio (Czechia) (CZ), Institute of Molecular Genetics (RU), Czech Academy of Sciences, Institute of Molecular Genetics (CZ)
Ústav Molekulární Genetiky, Akademie Věd České Republiky, Mikrobiologický Ústav, Akademie Věd České Republiky
Good health and well-being
Openalex Percentile: Top 6%
Immune Cell Function and Interaction
3.99
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.